anti-Patatin-Like phospholipase Domain Containing 3 (PNPLA3) Antibodies

The protein encoded by PNPLA3 is a triacylglycerol lipase that mediates triacylglycerol hydrolysis in adipocytes. Additionally we are shipping PNPLA3 Kits (18) and PNPLA3 Proteins (9) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
PNPLA3 80339 Q9NST1
PNPLA3 116939 Q91WW7
PNPLA3 362972  
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-PNPLA3 Antibodies at

Showing 10 out of 88 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Human Rabbit Un-conjugated IHC, WB Human Heart 100 μL 2 to 3 Days
Human Goat Un-conjugated ELISA, WB Antibody (0.05µg/ml) staining of Mouse Heart lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. Antibody (0.01µg/ml) staining of Mouse (A) and Rat (B) Adrenal gland lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 100 μg 6 to 7 Days
Human Rabbit Un-conjugated EIA, WB Western blot analysis in K562 cell line lysates (35ug/lane) using PNPLA3 Antibody (N-term) Cat.-No AP53370PU-N. This demonstrates the PNPLA3 antibody detected the PNPLA3 protein (arrow). 0.4 mL 6 to 8 Days
Bat Goat Un-conjugated ELISA, IHC, IHC (p), WB 50 μg 11 to 14 Days
Human Rabbit Un-conjugated IHC, IHC (p), WB 100 μL 11 to 14 Days
Human Rabbit Un-conjugated WB PNPLA3 Antibody (N-term)  western blot analysis in K562 cell line lysates (35ug/lane).This demonstrates the PNPLA3 antibody detected the PNPLA3 protein (arrow). 400 μL 10 to 11 Days
Dog Goat Un-conjugated EIA, IHC (p), WB   0.1 mg 4 to 8 Days
Mouse Rabbit Un-conjugated WB Mouse Pnpla3 Antibody (C-term)  western blot analysis in mouse kidney tissue lysates (35ug/lane).This demonstrates the Pnpla3 antibody detected the Pnpla3 protein (arrow). 400 μL 10 to 11 Days
Human Goat Un-conjugated ELISA, WB 0.1 mg 2 to 3 Days
Human Rabbit Un-conjugated IHC, ELISA, WB 100 μL 2 to 3 Days

Top referenced anti-PNPLA3 Antibodies

  1. Human Polyclonal PNPLA3 Primary Antibody for ELISA, WB - ABIN361184 : Kumari, Schoiswohl, Chitraju, Paar, Cornaciu, Rangrez, Wongsiriroj, Nagy, Ivanova, Scott, Knittelfelder, Rechberger, Birner-Gruenberger, Eder, Brown, Haemmerle, Oberer, Lass, Kershaw, Zimmermann et al.: Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. ... in Cell metabolism 2012 (PubMed)
    Show all 2 Pubmed References

  2. Human Polyclonal PNPLA3 Primary Antibody for ELISA, IHC - ABIN4278479 : Steinberg, Kemp, Watt: Adipocyte triglyceride lipase expression in human obesity. in American journal of physiology. Endocrinology and metabolism 2007 (PubMed)

More Antibodies against PNPLA3 Interaction Partners

Human Patatin-Like phospholipase Domain Containing 3 (PNPLA3) interaction partners

  1. Participants were genotyped for PNPLA3 rs738409 and TM6SF2 rs58542926 variants. PNPLA3 G variant was independently associated with nonalcoholic fatty liver disease.

  2. Excessive gestational weight gain (GWG) was noticed in women that were overweight or obese before pregnancy. Study found a significant association between the variant genotype of GNB3 rs5443 and excessive GWG. Similarly, the presence of variant genotype of PNPLA3 rs738409 in mothers was associated with a lower ponderal index (PI) in their newborns. Study found no associations between GCKR rs780094 and birth weight or PI.

  3. PNPLA3 and TM6SF2 are common genetic variants among nonalcoholic fatty liver disease patients; both PNPLA3 I148M and TM6SF2 E167K genotypes are associated with increases in the size of low density lipoprotein and high density lipoprotein particles, phenotypes considered atheroprotective

  4. This study showed that polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with with chronic hepatitis C-related hepatocellular carcinoma development in Japanese patients with chronic hepatitis C virus infection.

  5. The risk alleles in PNPLA3, GCKR or TM6SF2 were not found to be individually associated with the presence of a disease risk factor and were not significantly more common in non-alcoholic fatty liver disease of patients with raised serum PIIINP.

  6. Non-alcoholic fatty liver disease patients carrying PNPLA3 I148M are characterized by a prominent activation of hepatic stem/progenitor cell niche.

  7. The I148M PNPLA3 variant has been identified as the major common genetic determinant of Non-alcoholic fatty liver disease.

  8. this review focuses on the genetic component of NAFLD, namely, the role of the PNPLA3 gene polymorphism in the development and course of the disease, and States its progression, such as non-alcoholic steatohepatitis, liver cirrhosis and hepatocellular carcinoma [review]

  9. Although the PNPLA3 rs738409 G allele has been associated with the risk of steatosis in chronic hepatitis B patients, no association between this polymorphism and the risk of cirrhosis was seen.

  10. In heavy drinkers, PNPLA3 GG primarily correlated with signs of liver damage (steatohepatitis, ballooning) but less with steatosis. Upon alcohol withdrawal, PNPLA3 GG carriers showed a delayed inflammation-associated resolution of liver stiffness.

  11. This study was planned to test whether follicular fluid (FF) levels of patatin-like phospholipase domain containing 3-gene (PNPLA3:adiponutrin), preptin, kisspeptin, and amylin change in polycystic ovarian syndrome.

  12. The PNPLA3 gene is associated with NAFLD in Mexican population.

  13. The association of PNPLA3 and TM6SF2 with HCC risk was confirmed in the prospective cohort with ALD. A genetic score including PNPLA3 and TM6SF2 minor alleles showed a progressive significant increased risk of HCC in ALD patients. PNPLA3-rs738409 and TM6SF2-rs58542926 are inherited risk variants of HCC development in patients with ALD in a dose dependent manner.

  14. PNPLA3 rs738409 polymorphism appears to be related to the increased progression of liver fibrosis in hepatitis C virus infected patients.

  15. PNPLA3 rs738409 polymorphism is not only a factor significantly associated with the susceptibility of NAFLD, but also related to the susceptibility of aggressive disease

  16. the risk alleles showed different metabolic effects: PNPLA3 rs738409-G, the strongest genetic non-alcoholic fatty liver disease (NAFLD) risk factor, did not associate with metabolic changes. Metabolic effects of GCKR rs1260326-T were comparable in many respects to the fatty liver associations

  17. Mutations of both PNPLA3 and TM6SF2, together with smoking and drinking all served as risk factors for HBV-HCC. However, the mutation of single PNPLA3 appeared as a protective factor on HBV-HCC.

  18. In an Italian cohort of chronic hepatitis C patients, the association of PNPLA3 polymorphisms (rs738409 C/C, C/G, G/G) with liver steatosis was confirmed but there was no additive effect of MTP polymorphisms in the development of steatosis.

  19. Neither PNPLA3 nor TM6SF2 polymorphisms seem to contribute significantly towards an increased risk for deterioration of liver function in patients with primary sclerosing cholangitis. These results underscore the divergent mechanisms of liver damage in cholestatic conditions as compared to metabolic and viral liver diseases.

  20. In a Han Chinese population, the present study confirmed that PNPLA3 polymorphism rs738409 was more likely to influence the susceptibility to alcoholic liver disease.

Mouse (Murine) Patatin-Like phospholipase Domain Containing 3 (PNPLA3) interaction partners

  1. conclude that the fatty liver disease associated with genetic variation in PNPLA3 is not related to the enzyme's role in remodeling lipid droplets.

  2. Histone acetylation plays a role in the modulation of PNPLA3 levels in the liver exposed to binge ethanol drinking.

  3. 148M variant disrupts ubiquitylation and proteasomal degradation

  4. Neither ablation nor overexpression of wild-type PNPLA3 affects liver fat content in mice, whereas hepatic overexpression of the human 148M transgene causes steatosis.

  5. rs738409 exerts a marked influence on hepatocarcinogenesis in patients with cirrhosis of European descent.

  6. PNPLA3 plays a role in remodeling TAG in lipid droplets, as they accumulate in response to food intake

  7. adiponutrin/PNPLA3 is regulated by two key factors of the glycolytic and lipogenic pathways, raising the question of its implication in the metabolism of carbohydrates and lipids

  8. data argue against a role for Pnpla3 loss-of-function in fatty liver disease or metabolic syndrome in mice.

  9. Loss of Pnpla3 does not cause fatty liver, liver enzyme elevation, or insulin resistance in mice.

  10. Microarray-based gene profiling showed that the expression level of PNPLA3 in hepatocytes is correlated with that of genes associated with the lipogenic pathway such as ME1, SPOT14, and SCD1.

  11. data suggest that murine ATGL but not adiponutrin contributes to net adipocyte lipolysis and that ATGL and adiponutrin are oppositely regulated by insulin both in vitro and in vivo

PNPLA3 Antigen Profile

Protein Summary

The protein encoded by this gene is a triacylglycerol lipase that mediates triacylglycerol hydrolysis in adipocytes. The encoded protein, which appears to be membrane bound, may be involved in the balance of energy usage/storage in adipocytes.

Gene names and symbols associated with PNPLA3

  • patatin like phospholipase domain containing 3 (PNPLA3) antibody
  • patatin-like phospholipase domain containing 3 (Pnpla3) antibody
  • Adpn antibody
  • C22orf20 antibody
  • iPLA(2)epsilon antibody

Protein level used designations for PNPLA3

acylglycerol O-acyltransferase , adiponutrin , calcium-independent phospholipase A2-epsilon , iPLA2-epsilon , iPLA2epsilon , patatin-like phospholipase domain-containing protein 3

80339 Homo sapiens
116939 Mus musculus
362972 Rattus norvegicus
Selected quality suppliers for anti-PNPLA3 (PNPLA3) Antibodies
Did you look for something else?